All posts by imreal

Get 24/7 Access to Your Digital Health Records Using the Ravkoo App


Ravkoo Health, a trailblazing tech company focused on healthcare, has recently launched its mobile application. The Ravkoo Health App provides registered users with a digital space to securely store and manage their health records, empowering them with 24/7 access to their medical information via smartphone. This app also acts as a marketplace for members to book and consult with physicians, weight management coaches, and therapists while staying at the forefront of wellness trends.

Since July , 2021, the policies outlined in the May 2020 Interoperability and Patient Access final rule went into effect. These milestone provisions mean that Americans can now use third-party apps to access and download their health records, opening the doorway for companies like Ravkoo Health to create a platform where the patients are in charge of their medical data.

“This app offers the secure storage of a registered user’s electronic health records (EHRs) and provides them with a safe, cost-effective, and better-coordinated healthcare experience,” says Mayur Patel of Ravkoo Health.

“Furthermore, once authorized, our licensed telehealthcare providers gain the unique ability to pull a registered user’s past medical records resulting in a thorough consultation with full knowledge of a member’s medical history,” adds Patel.

The benefits of using the Ravkoo Health App to store electronic health records include:

Improved accessibility: Accessing health records from numerous providers can be daunting and seemingly impossible. Instead, the Ravkoo Health App empowers its registered users by providing them with a platform where they can access their records anytime, anywhere. This convenient retrieval goes a long way if a member needs to show a provider a record for current treatment quickly. Furthermore, our vetted providers can pull up to 85% of a member’s records from up to five years ago, removing the barrier of forgotten data.

Centralization and consolidation: With consent, our healthcare providers can pull up and confirm a registered user’s health records which are stored within the Summary section of the app. Because the records have been verified and are located within the menu bar, the member has a consolidated digital center to access their records effortlessly.

Better quality care: Our highly qualified pharmacists, doctors, counselors, and lab techs can refer to a registered user’s past medical and health records, enabling the provider to coordinate a treatment plan smoothly. The healthcare providers can also create a care plan for future reference allowing for continuity. Never before has it been so straightforward for a person to have most of their important medical data in one place.

Improved medical history storage: A registered user’s electronic health records can fall under any of the 13 Ravkoo Health Categories, which include: allergies, diagnoses, documents, educational videos, encounters, family history, forms, immunizations, medications, miscellaneous, plan of care, procedures, and lab results. The thorough list offers member’s a 365-degree view of their medical history, and the tech company continues to add to the categories.

Consolidated storage of electronic health records is now available on the ready-to-download Ravkoo Health App, free for iOS and Android (with pay-per-consultation). Visit Ravkoo Health to learn more.

About Ravkoo Health: Ravkoo Health harnesses the power of technology to give people control over their health information on a secure platform. Furthermore, ravkoo Health is emerging as a one-stop-shop digital healthcare marketplace. Online members of the app can access and store health data, choose and consult with telemedicine professionals, make prescription arrangements, order at-home lab kits, receive lab results over the phone, confer with weight loss, nutrition, and wellness coaches, track fitness, and access up-to-date health information.

Share article on social media or email:

Labor Lawyers, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Suit Against Monroe Operations, LLC for Allegedly Failing to Accurately Record Employees’ Time


Law Office of Blumenthal Nordrehaug Bhowmik De Blouw LLP

For more information about the class action lawsuit against Monroe Operations, LLC, call (800) 568-8020 to speak to an experienced California employment attorney today.

The Los Angeles employment law attorneys at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action complaint alleging that Monroe Operations, LLC violated the California Labor Code. The Monroe Operations, LLC, class action lawsuit, Case No. 30-2022-01268754-CU-OE-CXC, is currently pending in the Orange County Superior Court of the State of California. A copy of the Complaint can be read here.

The complaint alleges Monroe Operations, LLC allegedly failed to pay employees for all the time they were under the employer’s control. This, allegedly, includes the time Plaintiff and other California Class Members had to submit to mandatory COVID-19 questionnaires and temperature checks prior to clocking in for the day. To the extent that the time worked off the clock did not qualify for overtime premium payment, Defendant allegedly failed to pay minimum and overtime wages for the time worked off-the-clock.

Additionally, the lawsuit alleges Defendant underpaid minimum and overtime wages to Plaintiff and other California Class Members by failing to pay such wages at the regular rate of pay. Plaintiff received a non-discretionary bonus that was allegedly not calculated into the regular rate of pay, which resulted in an alleged underpayment of minimum and overtime wages.

For more information about the class action lawsuit against Monroe Operations, LLC, call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is an employment law firm with offices located in San Diego, San Francisco, Sacramento, Los Angeles, Riverside and Chicago that dedicates its practice to helping employees, investors and consumers fight back against unfair business practices, including violations of the California Labor Code and Fair Labor Standards Act. If you need help in collecting unpaid overtime wages, unpaid commissions, being wrongfully terminated from work, and other employment law claims, contact one of their attorneys today.

***THIS IS AN ATTORNEY ADVERTISEMENT***

Share article on social media or email:

BestRx Expands Its Software Capabilities to Help Independent Pharmacies Navigate New State-Specific Requirements


News Image

“We have seen how challenging new state and national requirements can be for independent pharmacies,” says Hemal Desai, President of BestRx. “We will continue develop solutions that enable our customers to remain compliant, while minimizing the impact it has on their daily workflow.”

BestRx continues to stay up to date on all pharmacy regulations – at both the national and state levels. Over the years, the company has expanded its software capabilities to help independent pharmacies quickly adapt and adhere to new regulations as they arise. By making these updates proactively, BestRx is further supporting its mission to evolve with the changing needs of its customers and provide all the tools needed to operate more efficiently.

Over the last month, BestRx rolled out several software updates that address state-specific requirements that went into effect in July. This includes functionality to support California’s new automatic refill law and the Positive ID requirement in Ohio. Additional details about what’s changed for pharmacies in these states, and how BestRx has responded is outlined below:

California’s New Auto-Refill Requirements

As of July 1, California requires pharmacies to obtain consent for every new prescription. This means automatic refills are no longer permitted without the patient’s consent. Under the new law, pharmacies now need to take additional steps to confirm a patient wants to participate in an auto refill program. This includes checking whether they want to continue to receive automatic refills (for each prescription) annually. Patients must also be permitted to stop auto-refills on a prescription or opt out of the program entirely at any time.

Understanding the impact these additional steps would have on the pharmacy, BestRx implemented a software update to ensure the pharmacy is compliant, while minimizing the impact on their daily workflow.

Ohio’s New Positive ID Requirement

Starting on June 30, Ohio pharmacies must capture positive identification of the pharmacist, technician or intern that are entering prescription information into their record keeping system. This includes any changes made to a script. Additionally, Pharmacies will need to maintain a daily record detailing who completed each step within the prescription workflow. These records must then be retained by the pharmacy for three years.

To help Ohio pharmacies satisfy this requirement, BestRx now has the ability to easily generate a Positive ID report at the end of each day. The pharmacy staff can use the report to view activities performed throughout the day. Once reviewed, the employees can sign the report, validating its accuracy. Then, the report can simply be filed in case of an audit.

“BestRx has seen firsthand, how challenging adapting to new requirements can be for independent pharmacies,” says Hemal Desai, President of BestRx. “We will continue to develop solutions that enable our customers to remain compliant as new regulations are implemented, while minimizing the impact on their daily workflow.”

In addition to these software updates, BestRx has also begun preparing for PDMP updates in several states. By staying informed on changes impacting industry and proactively developing new solutions, the company is ensuring its able to best support the needs of pharmacies in the future.

About BestRx: For nearly 40 years, BestRx has remained a family business focused on providing independent pharmacies with the tools needed to run their business more efficiently and profitably. Our intuitive, easy-to-use pharmacy management software features robust integrations and is backed by unparalleled customer service. Through our committed to ongoing innovation, BestRx will always be at the heart of growth. To learn more about BestRx, please visit: http://www.bestrx.com

Share article on social media or email:

Life Molecular Imaging announces presentation of new scientific data at the Alzheimer’s Association International Conference


Life Molecular Imaging @ AAIC 2022

Life Molecular Imaging @ AAIC 2022

PET Neuroimaging is broadly expanding, revealing new insights into pathophysiology and providing important biomarker data for diagnosing patients and in therapeutic clinical trials

Life Molecular Imaging (LMI) announces today that new research results on its approved and investigational positron emission tomography (PET) neuroimaging tracers will be presented at the Alzheimer’s Imaging Consortium (AIC) meeting and the Alzheimer’s Association International Conference (AAIC) in San Diego (July 30 – August 4, 2022), the biggest and most influential international meeting dedicated to advancing dementia science.

The contributions cover twelve (12) presentations demonstrating the utility of its approved compound Neuraceq® (florbetaben F18 injection), thirteen (13) presentations supporting the potential of its investigational tau tracer 18F-PI-2620 and one (1) presentation highlighting first-in-human data from its investigational neuroinflammation imaging tracer 18F-DED.

LMI is also proud to be contributing with The Amyloid imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative to the AAIC program. A virtual featured research session entitled “Progressing the clinical and technical value of amyloid PET in dementia – the AMYPAD experience” will be held on August 1st.

LMI in conjunction with Clario will host a reception and presentations of tau PET imaging, quantification and use in clinical trials featuring Dr. Victor Villemagne.

“We are impressed by the data that research groups around the world have collected over the last year,” said Dr. Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “PET Neuroimaging is broadly expanding, revealing new insights into pathophysiology and providing important biomarker data for diagnosing patients and in therapeutic clinical trials.”

Datasets involving LMI compounds presented at the AAIC conference include the following presentations:

Amyloid-PET Neuroimaging presentations involving Neuraceq® (florbetaben F18 injection):

July 30, 2022 (AIC)

  • Holy et al., Non-invasive quantification and SUVR validation of [18F]-florbetaben with total-body EXPLORER PET (Oral #IC_O-07-03, Ballroom 20D – San Diego Convention Center, 2:40pm – 2:55pm)


July 31, 2022

  • Hönig et al., Inverse relationship between education and amyloid burden in individuals with subjective cognitive decline plus and mild cognitive impairment (Virtual Poster, 7:00am – 11:55pm)
  • Altomare et al., The use of amyloid-PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study (Poster # P1-229, Exhibit Hall — DEF – San Diego Convention Center 9:15am – 4:45pm)
  • Petersen et al., Bilingualism Appears to be Protective Against Cognitive Decline Related to Amyloid Burden in Mexican Americans: An HABS-HD Study (Oral, Virtual Session (chairs and presenters only – Room 23A) – San Diego Convention Center, 9:27am – 9:39am)
  • Sala et al., Validation of a continuous model of amyloid-β CSF/PET discordance across cohorts and PET tracers (Poster # P1-192, 12:00am – 11:59pm)

August 1, 2022

  • Holy et al., Non-invasive quantification and SUVR validation of [18F]-florbetaben with total-body EXPLORER PET (Poster #P2-213, 12:00am – 11:59pm)
  • Shekari et al., Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution (Poster #P2-253, 12:00am – 11:59pm)


AMYPAD virtual featured research session “Progressing the clinical and technical value of amyloid PET in dementia – the AMYPAD experience”

  • Altomare et al., Steps towards the implementation of amyloid-PET in memory clinics: AMYPAD Diagnostic and Patient Management Study (Oral, Virtual Session (chairs and presenters only – Room 21) – San Diego Convention Center, 9:15am – 9:30am)
  • Shekari et al, Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution (Oral, Virtual Session (chairs and presenters only – Room 21) – San Diego Convention Center, 9:30am – 9:45am)
  • Collij et al., Quantitative amyloid-PET measures in a memory clinic population (Oral, Virtual Session (chairs and presenters only – Room 21) – San Diego Convention Center, 9:45am – 10:00am)
  • Vallez Garcia et al., First results of the AMYPAD Prognostic and Natural History Study: amyloid-PET centiloids predicts cognitive functioning in a pre-dementia population (Oral, Virtual Session (chairs and presenters only – Room 21) – San Diego Convention Center, 10:00am – 10:15am)


August 3, 2022

  • Vallez Garcia et al., First results of the AMYPAD Prognostic and Natural History Study: amyloid-PET centiloids predicts cognitive functioning in a pre-dementia population (Poster # P4-222, 12:00am – 11:59pm)

Tau-PET Neuroimaging presentations involving 18F-PI-2620:

July 30, 2022 (AIC)

  • Dore et al., CenTauRz: A standardized quantification of tau PET scans (Oral #IC_O-05-03, Ballroom 20D – San Diego Convention Center, 11:34am – 11:46am)
  • Bohorquez et al., In Vivo Head-To-Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease (Poster #IC-P-118, Exhibit Hall — DEF – San Diego Convention Center, 12:25pm – 1:40pm)
  • Roemer et al., Subcortical tau-accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R-tauopathies (Poster, # IC-P-117, Exhibit Hall — DEF – San Diego Convention Center, 12:25pm – 1:40pm)

July 31, 2022

  • Dore et al., CenTauRz: A standardized quantification of tau PET scans (Virtual Poster, 7:00am – 11:55pm)
  • Oh et al., One Year Longitudinal Change of Tau Accumulation on [18F]PI-2620 PET in Alzheimer Spectrum (Virtual Poster, 7:00am – 11:55pm)
  • Soleimani-Meigooni et al., [18F]PI-2620 PET in four-repeat tauopathies: a preliminary study (Poster # P1-230, Exhibit Hall — DEF – San Diego Convention Center, 9:15am – 4:45pm)
  • Mendez-Orellana et al., Tau-PET imaging with 18F-PI-2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s disease and patients with primary progressive aphasia (Virtual Poster, 7:00am – 11:55pm)
  • Petersen et al., Bilingualism Appears to be Protective Against Cognitive Decline Related to Cerebral Tau in Mexican Americans: An HABS-HD Study (Poster #P1-264, 9:15am – 4:45pm)

August 1, 2022

  • Sanabria Bohorquez et al., In Vivo Head-To-Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease (Poster #P2-232, 12:00am – 11:59pm
  • Chen et al., Generative Adversarial Network-Enhanced Ultra-low-dose [18F]-PI-2620 Tau PET/MR Imaging (Poster # P2-208, 12:00am – 11:59pm

August 2, 2022

  • Santibanez et al., Tau PET imaging with 18F-PI-2620 in patients with corticobasal syndrome: a case series (Poster #P3-181, 12:00am – 11:59pm)

August 3, 2022

  • Roemer et al., Subcortical tau-accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R-tauopathies (Oral, Ballroom 6A – San Diego Convention Center, 9:15am – 9:25am)
  • Santibanez et al, Tau and amyloid PET imaging with 18F-PI-2620 and 18F-Florbetaben in patients with early-onset dementia and healthy controls (Poster #P4-201, 12:00am – 11:59pm)

Neuroinflammation-PET Imaging involving 18F-DED

August 2, 2022

  • Katzdobler et al., First-in-human [18F]D2-Deprenyl-PET imaging and GFAP evaluation as biomarkers of reactive astrogliosis in neurodegenerative diseases (Poster #P3-409, 12:00am – 11:59pm)

About Neuraceq® (florbetaben 18F)

Indication

Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

A negative Neuraceq® scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations.

Limitations of Use

  • A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder.
  • Safety and effectiveness of Neuraceq® have not been established for (i) predicting development of dementia or other neurologic conditions and (ii) monitoring responses to therapies.

Important Safety Information

Risk for Image Interpretation and Other Errors

Neuraceq® can be used to estimate the density of beta-amyloid neuritic plaque deposition in the brain. Neuraceq® is an adjunct to other diagnostic evaluations. Neuraceq® images should be interpreted independent of a patient’s clinical information. Physicians should receive training prior to interpretation of Neuraceq® images. Following training, image reading errors (especially false positives) may still occur. Additional interpretation errors may occur due to, but not limited to, motion artifacts or extensive brain atrophy.

Radiation Risk

Administration of Neuraceq®, like other radiopharmaceuticals, contributes to a patient´s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. It is important to ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Most Common Adverse Reactions

In clinical trials, the most frequently observed adverse drug reactions in 872 subjects with 1090 Neuraceq® administrations were injection/application site erythema (1.7%), injection site irritation (1.1%), and injection site pain (3.4%).

About PI-2620

Tau deposits, in conjunction with beta-amyloid plaques, represent the other pathological hallmark of Alzheimer’s disease, with tau deposits further playing an important role in other neurodegenerative diseases. PI-2620 is binding to 3R/4R and 4R tau deposits and is a next generation 18F-labeled investigational PET tracer with favourable properties and imaging characteristics. It was discovered in a research collaboration between Life Molecular Imaging and AC Immune, a Swiss-based clinical stage biopharmaceutical company. Life Molecular Imaging has the exclusive, world-wide license for research, development and commercialization of tau PET tracers generated within the discovery program.

About 18F-DED

Neuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by activated astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity.

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit https://life-mi.com.

About Life Healthcare Group

Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT and PET scans) within Europe, operating internationally across 10 countries. Life Molecular Imaging, a division of Alliance is an integrated pharmaceutical business that includes research and development laboratories, access to a network of cyclotrons and radio-pharmacies and imaging facilities, with Life Radiopharma being Alliance’s distributor of radiopharmaceuticals to diagnose many types of diseases. Visit https://www.lifehealthcare.co.za/

Share article on social media or email:

Breathe Easier with the New Spontaneous Breathing Lung Simulator from Michigan Instruments


“The Spontaneous Breathing Lung has been one of our most requested device capabilities for our Lung Simulators. It provides an easier way for researchers, educators and developers to access these capabilities on our devices.”

Michigan Instruments, a leading manufacturer in Lung Simulators, is proud to announce the release of their new Spontaneous Breathing Lung Simulator (SBL™). The SBL™ is capable of providing precision-based simulation of a breathing patient to aid in the research, training, and development of non-invasive and supportive modes of ventilation and oxygenation.

The Spontaneous Breathing Lung Simulator offers an updated way to create spontaneous breathing. This is available as an independent device or an add-on to the current version of Michigan Instruments’ TLL Training Test Lungs and PneuView systems. The addition of the SBL module, transforms the device into a spontaneous breathing system.

“The Spontaneous Breathing Lung has been one of our most requested device capabilities for our Lung Simulators,” said Chris Blanker, owner and president of Michigan Instruments. “We’ve had an alternative option using our Breath Simulation Module, but the Spontaneous Breathing Lung provides an easier way for researchers, educators and developers to access these capabilities on our devices.”

While the Spontaneous Breathing Lung is useful in any research requiring breathing, in training settings the Spontaneous Breathing Lung can help educators create a variety of scenarios and breathing patterns that can be used during student education in classrooms and simulation labs. While in testing settings, the simulator can help facilitate troubleshooting and testing of devices meant to operate on spontaneous breathing patients and test various device capabilities.

The Spontaneous Breathing Lung is capable of providing users with a variety of real-time data, including:


  • Breath rates of 2 to 30 breaths per minute
  • Inspiratory Time of .5 to 5.0 seconds in .1 second increments
  • Breath Volume of 100 – 1,800 ml
  • Flow Waveform: Square or Sinusoid

To learn more about Michigan Instruments Spontaneous Breathing Lung Simulator, visit http://www.michiganinstruments.com/lung-simulators/spontaneous-breathing-lung/

About Michigan Instruments

Michigan Instruments has designed and manufactured specialized medical equipment related to the fields of cardiovascular medicine, Automated CPR, respiratory therapy and lung simulation for over fifty years.

The company has built a reputation for medical device products of exceptional quality, which has earned the respect of thousands of customers, associates, and medical professionals throughout the world. For more information, visit http://www.michiganinstruments.com

Share article on social media or email:

Transforming Point-of-Care Diagnostic Testing, Upcoming Webinar Hosted by Xtalks


Next-generation POC testing, different from traditional lateral flow tests, is proving its ability to deliver highly sensitive testing with actionable test results within minutes.

Advancements in point-of-care (POC) testing are impacting health systems.

COVID-19 exposed tremendous gaps in health systems and access to testing. Importantly, it also showed the need for rapid and reliable testing to safely reopen schools, return to the workplace and reopen the economy. In this webinar, the featured speaker will review the impact of next-generation POC testing during the pandemic and beyond and explain the science powering this testing technology.

Moving testing from huge, central laboratories to rapid, portable devices has been a pivotal change in medical technology. Previously, testing performance and speed were at odds, but because of recent technological advancements, it’s now possible to deliver both. Next-generation POC testing, different from traditional lateral flow tests, is proving its ability to deliver highly sensitive testing with actionable test results within minutes.

Join this webinar to learn the science and opportunities behind next-generation point-of-care testing and how providers are integrating this into their patient care pathways.

Join Dr. Nigel Lindner, PhD, Chief Innovation Officer, LumiraDx, for the live webinar on Monday, August 22, 2022, at 1pm EDT (10am PDT/ 8pm KSA).

For more information, or to register for this event, visit Transforming Point-of-Care Diagnostic Testing.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Roland DGA’s DGSHAPE Americas Dental Business Group Announces Key Changes to its Leadership Team


New and recently promoted staffers strengthen Roland DGA's DGSHAPE dental team.

Pictured above: Jimmy Ruiz, DGSHAPE Dental Business Manager; Lisa Aguirre DGSHAPE Dental Marketing Manager; Juan Molina, DGSHAPE Dental Product Manager; and Brian Kinard, DGSHAPE Dental Sales Rep.

“Their combined experience and skills will strengthen DGSHAPE’s position as a leader in digital dental equipment for labs, and help maximize interest and awareness in our chairside solutions for clinics.”

Roland DGA’s DGSHAPE Americas business group, a leading provider of advanced dental milling machines, 3D printers, and accessories for the laboratory and clinical markets, has announced key personnel changes to its leadership team.

Jimmy Ruiz, a dental industry veteran with more than 16 years of experience in the field, has been hired as DGSHAPE Dental Business Manager. In his new position with Roland DGA, Ruiz will be responsible for the oversight of all dental activities in the Americas, including management of sales, marketing, product management, and service personnel.

Lisa Aguirre, previously DGSHAPE Dental Product Manager, has been promoted and will assume the newly created position of DGSHAPE Dental Marketing Manager. Aguirre’s new responsibilities will include planning, implementing, and analyzing marketing strategies and campaigns, overseeing events, promotions, and public relations, as well as delivering communications across a variety of mediums and channels.

Juan Molina, who has held several positions within Roland DGA’s customer service and technical support departments over the past 10 years, most recently serving as DGSHAPE Dental Technical Representative, has been promoted to the position of DGSHAPE Dental Product Manager. In his new role, Molina will manage all aspects of the dental product portfolio, develop strategies based on customer and market input, and help bring new products and solutions to market.

Additionally, Brian Kinard has joined the company as DGSHAPE Dental Sales Representative for the Western U.S. region. Kinard brings with him more than 20 years of experience in the dental field. As Roland DGA’s newest DGSHAPE Dental Sales Representative, Kinard’s responsibilities will include growing, managing, and supporting the dealer channel for his region through sales and post-sale support.

“We are confident that each of these talented, dedicated individuals will contribute greatly to the overall success of our DGSHAPE dental division,” said Roland DGA’s Vice President of Sales, Amado Lara. “Their combined experience and skills will strengthen DGSHAPE’s position as a leader in digital dental equipment for labs, and help maximize interest and awareness in our chairside solutions for clinics.”

To learn more about Roland DGA’s DGSHAPE dental products, visit http://www.dgshapeamericas.com. For more information on Roland DGA Corporation or the complete Roland DGA product line, visit https://www.rolanddga.com.

About Roland DGA Corporation and DGSHAPE Americas

Roland DGA Corporation serves North and South America as the marketing, sales, distribution, and service arm for Roland DG Corporation and its subsidiary, DGSHAPE. Founded in 1981 and listed on the Tokyo Stock Exchange, Roland DG of Hamamatsu, Japan is a worldwide leader in wide-format inkjet printers, engravers, photo impact printers, and CNC milling machines. DGSHAPE Americas is the Roland DGA dental business group dedicated to the DGSHAPE line of products, most notable as a market leader in dental milling machines.

Share article on social media or email:

Your Face MD Embraces Innovation With Acquisition of Clarity II Laser Hair Removal Machine


Dr. Ran Rubinstein, commonly known as “Your Face MD,” acquires a state-of-the-art Clarity II Laser Hair Removal Machine. Clarity II is a digitally powered, dual-wavelength platform laser from Lutronic Intelligent Care. Ran Rubinstein MD Laser & Cosmetic Surgery Specialists is thrilled to improve patient experience and care by acquiring this intelligent device. When using Clarity II, laser hair removal treatments can be completed two times faster with greater efficacy when removing fine hairs. Dr. Rubinstein’s med spa patients will have the opportunity to remove unwanted body hair in less time with fewer sessions using this device. As a renowned facial plastic surgeon in Hudson Valley, New York, Dr. Rubinstein is devoted to serving his patients with the safest and most effective medical equipment.

Ran Rubinstein MD Laser & Cosmetic Surgery Specialists provide a wide range of top-tier med spa services, including CoolSculpting, hair restoration, QWO cellulite treatment, and laser treatments. In addition to laser spider vein and stretch mark removal procedures, laser hair removal is a highly sought-after non-invasive treatment. Male and female patients interested in removing unwanted facial or body hair can participate in laser hair removal treatments quickly and safely. When it comes to hair removal treatments, laser hair removal is the gold standard in terms of pain, convenience, and efficiency. Dr. Rubinstein has recently upgraded to the Clarity II Laser Hair Removal Machine to provide faster and more effective treatments for patients of all skin types. This brilliant machine utilizes IntelliTrak™ technology to deliver more consistent treatment coverage throughout large areas. Clarity II also provides Dr. Rubinstein and his team with real-time skin temperature feedback and shorter pulse widths throughout the procedure.

Dr. Rubinstein has devoted his career to furthering medicine by training future surgeons as a clinical professor and leading physician trainer. Along with giving back to the medical community, Dr. Rubinstein is an active member of the American Society for Laser Medicine and Surgery. Dr. Rubinstein’s vast professional experience and commitment to patient care have earned him a reputation for excellence among his peers, students, and patients. Patient satisfaction and comfort, along with positive experiences, are at the forefront of Dr. Rubinstein’s medical practice. For this reason, patients routinely travel and specifically seek out Dr. Rubinstein’s highly specialized services for aesthetic laser and injectable procedures. Dr. Rubinstein serves his patients with unparalleled laser, cosmetic, and reconstructive surgery expertise as a dual board-certified facial plastic surgeon.

Dr. Ran Rubinstein, the leading aesthetic care provider in Hudson Valley, is excited to provide patients with faster and more effective laser hair removal treatments using the new Clarity II machine. To learn more about laser hair removal treatments at Your Face MD, please visit https://www.yourfacemd.com/.

Share article on social media or email:

Super Early Bird Price Ending Aug. 5 for WCG MAGI Clinical Research Conference 2022 West


Super Early Bird pricing ends Aug. 5 for WCG MAGI Clinical Research Conference 2022 West.

WCG MAGI Clinical Research Conference 2022 West

Oct. 16-19, 2022

Planet Hollywood Las Vegas Resort & Casino, Las Vegas, NV

https://wcg.swoogo.com/MAGI-West

WCG MAGI conferences are the best value in clinical research. Which is why attending WCG MAGI Clinical Research Conference 2022 West makes great business sense, giving clinical trial professionals the actionable information and connections needed to enhance their clinical trials.

And right now, the best value is an even better value at $400 off. Super Early Bird pricing ends on Aug. 5, 2022.

Attendees choose from more than 70 sessions addressing the biggest clinical trial issues. After past conferences participants returned to their organization with an average of 10 practical tips they implemented for better clinical trials.

Whether they are from a sponsor, research site or CRO, a newcomer to the industry, a senior executive or somewhere in between, attendees will find what they need at WCG MAGI West, including:


  • Ensuring Appropriate Representation in Clinical Trials to Advance Medicine and Reduce Health Disparities


Design practical, proactive diversity plans that better advance excellence in clinical research with this session. The session includes a discussion of the FDA’s recent draft guidance on clinical trial diversity plans and the work being done to promote health equity and reduce health disparities through the clinical research enterprise within the FDA’s Office of Minority Health and Health Equity.

  • A Pro/Con Debate: Clinical Trials “as a Care Option”


In this session, two speakers debate whether the current trend of referring to “clinical trials as a care option” is a positive statement that reinforces that research participants should be offered to all patients as part of medical care or a statement that inappropriately blurs the line between medical care and clinical research, creating a therapeutic misconception.

  • Keynote by Mary Elizabeth Williams, On the Importance of Clinical Research: A Patient’s Perspective


This patient advocate, journalist, and health and science writer — also a stage IV melanoma survivor thanks to the Phase 1 immunotherapy clinical trial that saved her life — will discuss the importance of strong healthcare communication in the clinical trial setting. A doctoral candidate in Medical Humanities at Drew University, she’ll share how collaborative, empathetic techniques can improve enrollment, retention and outcomes.

  • The Best Professional Networking Anywhere


WCG MAGI conferences are all about lasting relationships. Throughout the four-day event, facilitated peer-to-peer networking will help participants meet people from all areas of the clinical research industry and strengthen existing relationships.

WCG MAGI Clinical Research Conference 2022 West will empower participants to take their clinical trials to the next level. Register by Aug. 5 to get the Super Early Bird savings.

Conference Details:

WCG MAGI Clinical Research Conference 2022 West

Oct. 16-19, 2022

Planet Hollywood Las Vegas Resort & Casino, Las Vegas, NV

https://wcg.swoogo.com/MAGI-West

Price:

All-Access Pass:

Super Early Bird: Register by Aug. 5, 2022 — $1,095

Early Bird: Register by Sept. 16, 2022 — $1,295

After Sept. 16, 2022 — $1,495

Includes all workshops, panel discussions, sessions, meals and exhibit hall access.

Preconference Workshops Only Pass – $345.00

Includes access to the preconference workshops on Sunday only. Lunch is included.

Exhibit Hall Only Pass – $125.00

Includes access to the exhibit hall only. Lunch is not included.

Easy Ways to Register:

Online: https://wcg.swoogo.com/MAGI-West

By phone: 888.838.5578 or 703.538.7600

About WCG MAGI Conferences:

WCG MAGI events connect clinical research professionals who share a deep commitment to ensuring the quality, compliance, and efficiency of clinical research that is needed to advance the delivery of therapies and devices that impact patient’s lives. Professionals who attend WCG MAGI conferences benefit from: comprehensive programing including best-in-class training from seasoned faculty; standardization of best practices for clinical operations, business, and regulatory compliance; innovation forums; and peer-to-peer networking. Most importantly, the WCG MAGI experience strengthens collegiality in a way that ensures the growth and success of clinical research.

Share article on social media or email:

DuPont Officially Opens New Biopharma Tubing Manufacturing Site in the U.S.


Cutting the ceremonial ribbon at the grand opening of the DuPont Healthcare Cooper River site in South Carolina, USA

“The Cooper River site will bring additional production capacity online over the next two years to serve strategic customers and expand our Liveo™ Healthcare Solutions customer base,” said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino

DuPont (NYSE:DD) today celebrated the opening of its new DuPont™ Liveo™ Healthcare Solutions manufacturing facility located at the Cooper River Site in South Carolina with a formal ribbon-cutting ceremony attended by state and local government officials and business leaders. The new facility will expand capacity for biopharmaceutical tubing extrusion to meet increased demand from Liveo™ customers.

The site, located near Moncks Corner, South Carolina operates using the same quality standards as the DuPont Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan – DuPont’s long-standing healthcare manufacturing site. Operators at the new South Carolina facility were certified at HIMS.

“The Cooper River site will bring additional production capacity online over the next two years to serve strategic customers and expand our Liveo™ Healthcare Solutions customer base,” said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino. “We’re committed to investing in our healthcare business, and this biopharma processing manufacturing investment at Cooper River is a key milestone in our growth strategy that will help us offer a highly reliable and sustainable product supply.”

DuPont worked with local companies – including more than 40 subcontractors on the site expansion project.

“Being selected as the second dedicated healthcare site is indeed an honor and a reflection of our team’s track record of dedication, ownership, and commitment to our Core Values and excellence in meeting customers’ needs. Thanks to collaboration between the DuPont team and our contractor partners, the Cooper River site was completed within 17 months – on time, on budget, and without a single recordable safety incident,” said Bill Alexander, DuPont Cooper River site leader. “The opening of the site already has enabled the creation of 25 jobs for startup, with another 25 expected by mid-2024 as we ramp up operations.”

The ribbon-cutting event included remarks from South Carolina Governor Henry McMaster, Berkeley County Supervisor Johnny Cribb, DuPont Electronics & Industrial Vice President and General Manager Sam Ponzo, Toccalino, and Alexander. Attendees also toured the site.

DuPont is demonstrating its commitment to serving the healthcare market and its customers with this expansion of its manufacturing footprint, offering high-quality, high-performance solutions, and supporting regulatory actions that address healthcare customers’ specific needs and challenges.

In addition to the Cooper River expansion, in the second half of 2022, the company expects to add biopharma silicone tubing capacity in China to serve the fast-growing customers in that region.

About DuPont™ Liveo™ Healthcare Solutions

DuPont™ Liveo™ is a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Electronics & Industrial

DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

Overview

On November 2, 2021, DuPont announced it has entered definitive agreements to acquire Rogers Corporation (“Rogers”), (the “Intended Rogers Acquisition”). On January 25, 2022, Rogers’s shareholders approved the transaction. Closing is expected in early third quarter 2022, subject to regulatory approvals and customary closing conditions.

On February 18, 2022, DuPont announced that it has entered into definitive agreements to divest a majority of its historic Mobility & Materials segment, excluding certain Advanced Solutions and Performance Resins businesses, to Celanese Corporation (“Celanese”), (the “M&M Divestiture”). Closing is expected around the end of 2022, subject to regulatory approvals and customary closing conditions. The Company also announced on February 18, 2022, that its Board of Directors has approved the divestiture of the Delrin® acetal homopolymer (H-POM) business. In addition to the entry into definitive agreements, the Company anticipates that the closing of the sale of Delrin® would be subject to regulatory approvals and other customary closing conditions, (the “Delrin® Divestiture” and together with the M&M Divestiture, the “M&M Divestitures”).

As of March 31, 2022, the results of operations and the assets and liabilities of the businesses in scope for the M&M Divestitures are presented as discontinued operations for all periods presented. The cash flows of these businesses have not been segregated and are included in the interim Consolidated Statement of Cash Flows. Unless otherwise indicated, the discussion of results, including the financial measures further discussed below refer only to DuPont’s Continuing Operations and do not include discussion of balances or activity of the businesses in scope for the M&M Divestitures. The Auto Adhesives & Fluids, Multibase™ and Tedlar® product lines previously within the historic Mobility & Materials segment (the “Retained Businesses”) are not included in the scope of the intended divestitures. The Retained Businesses are reported in Corporate & Other. The reporting changes have been retrospectively applied for all periods presented.

Cautionary Statement about Forward-looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the M&M Divestiture to Celanese, including (x) any failure to obtain necessary regulatory approvals, anticipated tax treatment or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value, timing or pursuit of the proposed transaction, and (z) risks and costs and pursuit and/or implementation, timing and impacts to business operations of the separation of business lines in scope for the M&M Divestiture to Celanese, (ii) the timing and outcome of the Delrin® Business Divestiture, including entry into definitive agreements, and the risks, costs and ability to realize benefits from the pursuit of the Delrin® Business Divestiture; (iii) ability to achieve anticipated tax treatments in connection with mergers, acquisitions, divestitures and other portfolio changes actions and impact of changes in relevant tax and other laws; (iv) indemnification of certain legacy liabilities; (v) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (vi) failure to timely close on anticipated terms (or at all), realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with mergers, acquisitions, divestitures and other portfolio changes including the Intended Rogers Acquisition and the M&M Divestitures; (vii) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to operational and supply chain impacts or disruptions, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geo-political and weather related events; (viii) ability to offset increases in cost of inputs, including raw materials, energy and logistics; (ix) risks, including ability to achieve, and costs associated with DuPont’s sustainability strategy including the actual conduct of the company’s activities and results thereof, and the development, implementation, achievement or continuation of any goal, program, policy or initiative discussed or expected,; and (x) other risks to DuPont’s business, operations; each as further discussed in DuPont’s most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

# # #

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

07/28/22

For further information contact:

Fiona Paul Pinter

Global Communications Leader, Healthcare

+41 79 5713084

fiona.paul-pinter@dupont.com

Image:

High resolution:

Low resolution:

Proposed caption:

Cutting the ceremonial ribbon at the grand opening of the DuPont Healthcare Cooper River site in South Carolina, USA, were (left to right) Cooper River Mobility & Materials Site Leader Bill Alexander; DuPont™ Liveo™ Cooper River Operations Representative and Construction Team Member Lincoln Weathersby; DuPont Electronics & Industrial Vice President of Integrated Operations John Singer; DuPont™ Liveo™ Cooper River Operator Mechanic CJ Jacobs; DuPont Electronics & Industrial Vice President and General Manager for Industrial Solutions Sam Ponzo; South Carolina Governor Henry McMaster; DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino; Berkeley County, South Carolina, Supervisor Johnny Cribb; Cooper River Project Team Leader Jen Crock; Cooper River North Area Leader Ellie DeSanto; DuPont™ Liveo™ Cooper River Operator Mechanic Cary Domi; and Cooper River Electronics & Industrial Site Leader Tony Schwuchow.